Skip to main content
. Author manuscript; available in PMC: 2006 May 30.
Published in final edited form as: Curr Top Med Chem. 2005;5(6):547–555. doi: 10.2174/1568026054367629

Table 1.

Protein Name Accession # Tissue Distribution KO phenotype Rank Order Potency of Antagonists
NKCC1 NM_001046 kidney, epithelium, CNS, sensory neurons (DRG, TG, olfactory) Male infertility, deafness, shaker, hypoalgesia bumetanide >> piretanide > furosemide
NKCC2 NM_000338 Kidney specific Renal insufficiency, Barrter syndrome
KCC1 NM_005072 Ubiquitous No KO mice
KCC2 AF208159 CNS, not DRG, TG CNS hyperexcitability, epileptic activity piretanide > furosemide ≈ bumetanide
KCC3 AF314956 Ubiquitous Sensorymotor neuropathy
KCC4 NM_006598 Ubiquitous, little in CNS Deafness